- URL: http://www.lifesciencetraininginstitute.com/doc/fda-guidance-on-social-media-questions-answered-and-unanswered-0001
- Date: 12/01/2016
- Listed: November 14, 2016 10:39 am
- Expires: This ad has expired
FDA Guidance on Social Media: Questions Answered and Unanswered
Date: December 1, 2016
Time: 1:00pm-2:30pm, EST US
Duration: 90 Minutes – Online
Price: $299 – Includes Bonus Handouts!
PLEASE NOTE: This course focuses on the FDA Guidance on Social Media related to the promotion of approved products. It does not cover the use of social media in clinical or other non-commercial settings.
Ever since FDA’s 2009 hearings on the Internet and social media platforms, industry has been anxiously awaiting guidance from the FDA on the proper use of social media to promote approved products. With a flurry of guidances released in 2014, FDA provided significant information for makers of prescription products who want to engage in social media channels that consumers and healthcare professionals are increasingly using to access healthcare information.
This session will provide an overview of the state of FDA guidance on social media with an emphasis on explaining where FDA has provided guidance on compliant use of social media and where FDA has failed to provide guidance. Additionally, this session will discuss how you can implement and manage programs to mitigate compliance and brand risk with an emphasis on the space-limited contexts such as Google text ads that started FDA’s focus.
Join our interactive online training course where you will learn:
The current state of FDA guidance on social media
Timing and next steps from FDA
Settled areas of FDA guidance that are unlikely to change
Controversial FDA positions that are likely to be revised
Key issues of remaining uncertainty
Risks vs. Benefits: “Selling” management on the importance of social media
Managing your social media activities to protect your brand
What’s worked, what hasn’t, and what’s happened as a result
Who Should Attend
This course will benefit senior decision makers who are determining whether to “green light” social media initiatives, marketers of prescription products who are trying to use social media, and regulatory professionals who are tasked with ensuring compliance of social media promotional tactics.
Information about the ad poster
- Listed by: email@example.com
- Member Since: September 7, 2016
Other items listed by firstname.lastname@example.org
- Understanding & Implementing The New NIH & FDA Draft Clinical Trial Protocol Template (RECORDED)
- Medical Device Design Controls 101 – A Practical Crash Course
- The Future Of Outsourcing In Clinical Research – Preparing For A Changing Global Landscape
- Quality by Design (QbD): Making Sense of the ICH Q8, Q9, Q10 Puzzle
- The New Medical Device Single Audit Program (MDSAP) for Manufacturers – Analyzing Rewards and Challenges